← Browse by Condition
Medical Condition

her2

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for her2 sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — her2 Clinical Trials

How many clinical trials are currently recruiting for her2?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for her2, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for her2?
her2 research spans Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a her2 clinical trial?
Eligibility criteria for her2 trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
2
Top Sponsors
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 1 trial
Zhejiang Cancer Hospital 1 trial
Xiujuan Qu 1 trial

Recruiting Clinical Trials

NCT07030569
Recruiting
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
Enrollment
500 pts
Location
Italy
Sponsor
Fondazione IRCCS Istituto Nazi...
View Trial →
NCT07285941 Phase 2
Recruiting
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
Enrollment
20 pts
Location
China
Sponsor
Zhejiang Cancer Hospital
View Trial →
NCT07506057 Phase 2
Recruiting
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
Enrollment
20 pts
Location
China
Sponsor
Xiujuan Qu
View Trial →

Related Conditions

radiomic (1) radiomics (1) breast cancer metastatic (1) breast cancer stage iv (1) breast carcinoma (1) breast neoplasms (1) breast cancer (1) breast cancer with bone metastasis (1) breast cancer with metastatic bone disease (1) trastuzumab (1) her2 breast cancer (1) her2 positive breast carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology